VesiCulture
/ AJ Vaccines
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
October 29, 2024
SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
(clinicaltrials.gov)
- P3 | N=1135 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting
Combination therapy • Enrollment closed • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
April 24, 2024
SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
(clinicaltrials.gov)
- P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Sep 2030 ➔ Sep 2029
Combination therapy • Trial completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
March 28, 2024
SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
(clinicaltrials.gov)
- P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: May 2030 ➔ Sep 2030
Combination therapy • Trial completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
February 16, 2024
SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
(clinicaltrials.gov)
- P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: May 2030 ➔ Sep 2029
Combination therapy • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
April 12, 2023
SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer
(clinicaltrials.gov)
- P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
February 06, 2023
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer
(clinicaltrials.gov)
- P3 | N=1050 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC
Combination therapy • New P3 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
September 29, 2022
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
(clinicaltrialsregister.eu)
- P3 | N=700 | Ongoing | Sponsor: Janssen-Cilag International NV
New P3 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
1 to 7
Of
7
Go to page
1